男性慢性肝病患者勃起功能障碍研究进展*

doi:10.3969/j.issn.1672-5069.2021.06.042

摘要/Abstract

摘要： 目的肝脏是性激素、脂质等多种物质代谢的重要器官。男性慢性肝病患者常合并性激素代谢紊乱、糖脂代谢紊乱和精神心理疾病等,容易发生勃起功能障碍,对患者的身心健康和家庭生活造成影响。现有研究表明,男性慢性肝病患者勃起功能障碍患病率在24.6%～85.0%之间,慢性肝炎患者勃起功能障碍患病率为8.6%～78.0%,而肝硬化患者勃起功能障碍患病率为41.2%～92.0%。本文对男性慢性肝病患者发生勃起功能障碍的发病状况、影响因素、可能的发病机制和治疗研究进展进行综述,期望引起广泛的关注,改善患者的身心健康。

关键词: 肝硬化, 慢性肝炎, 勃起功能障碍, 磷酸二酯酶抑制剂5

Abstract: Objective Liver is an important organ for the metabolism of sex hormones, lipids and other substances. Male patients with chronic liver disease often suffer from a variety of dysfunctions, such as sex hormone metabolism, glucose and lipid metabolism and mental and psychological disorder. Erectile dysfunction is easy to occur, which affects the physical and mental health and the family life of patients.Existing studies have shown that the prevalence of male erectile dysfunction in patients with chronic liver disease was 24.6% to 85%, the prevalence in chronic hepatitis patients was 8.6% to 78%, and in patients with cirrhosis was 41.2% to 92%.In this paper, we reviewed the incidence, impacting factors, possible pathogenesis, and treatment of erectile dysfunctions in male patients with chronic liver disease.

Key words: Cirrhosis, Chronic hepatitis, Erectile dysfunctions, Phosphodiesterase inhibitor 5

邓江, 石娟娟, 党双锁. 男性慢性肝病患者勃起功能障碍研究进展^*[J]. 实用肝脏病杂志, 2021, 24(6): 934-937.

Deng Jiang, Shi Juanjuan, Dang Shuangsuo. Erectile dysfunction in male patients with chronic liver diseases[J]. Journal of Practical Hepatology, 2021, 24(6): 934-937.

参考文献

[1] Zhang X, Yang B, Li N, et al. Prevalence and risk factors for erectile dysfunction in chinese adult males. J Sex Med, 2017, 14(10): 1201-1208.
[2] Yafi F A, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers, 2016, 2: 16003.
[3] Ludwig W, Phillips M. Organic causes of erectile dysfunction in men under 40. Urol Int, 2014, 92(1): 1-6.
[4] 方庆华, 胡雷, 陈栋. 代谢综合征与勃起功能障碍相关机制的研究进展. 中华肥胖与代谢病电子杂志, 2017, 3(3): 158-161.
[5] Kim M, Kim S Y, Rou W S, et al. Erectile dysfunction in patients with liver disease related to chronic hepatitis B. Clin Mol Hepatol, 2015, 21(4): 352-357.
[6] Toda K, Miwa Y, Kuriyama S, et al. Erectile dysfunction in patients with chronic viral liver disease: its relevance to protein malnutrition. J Gastroenterol, 2005, 40(9): 894-900.
[7] Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis b disease, China. Bull World Health Organ, 2019, 97(3): 230-238.
[8] Gentile I, Fusco F, Buonomo A R, et al. Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. Sex Health, 2018, 15(5): 408-412.
[9] Paternostro R, Heinisch B B, Reiberger T, Et Al. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver Int, 2018, 38(8): 1427-1436.
[10] Chrysant S G. Antihypertensive therapy causes erectile dysfunction. Curr Opin Cardiol, 2015, 30(4): 383-390.
[11] Thakur J, Rathi S, Grover S, et al. Tadalafil, a phosphodiesterase-5 inhibitor, improves erectile dysfunction in patients with liver cirrhosis. J Clin Exp Hepatol, 2019, 9(3): 312-317.
[12] Simsek I, Aslan G, Akarsu M, et al. Assessment of sexual functions in patients with chronic liver disease. Int J Impot Res, 2005, 17(4): 343-345.
[13] Cornely C M, Schade R R, Van Thiel D H, et al. Chronic advanced liver disease and impotence: cause and effect?Hepatology, 1984, 4(6): 1227-1230.
[14] Rachdaoui N, Sarkar D K. Pathophysiology of the effects of alcohol abuse on the endocrine system. Alcohol Res, 2017, 38(2): 255-276.
[15] Durazzo M, Premoli A, Di Bisceglie C, et al. Male sexual disturbances in liver diseases: what do we know? J Endocrinol Invest, 2010, 33(7): 501-505.
[16] Siervo G E, Vieira H R, Ogo F M, et al. Spermatic and testicular damages in rats exposed to ethanol: influence of lipid peroxidation but not testosterone. Toxicology, 2015, 330: 1-8.
[17] Lang Z W. Distribution of hepatitis B virus in testicle tissue in patients with hepatitis B infection. Zhonghua Yi Xue Za Zhi, 1993, 73(6): 329-331, 379.
[18] Sun P, Zheng J, She G, et al. Expression pattern of asialoglycoprotein receptor in human testis. Cell Tissue Res, 2013, 352(3): 761-768.
[19] Huang F, Long F, Yu W, et al. High prevalence of hepatitis E virus in semen of infertile male and causes testis damage. Gut, 2018, 67(6): 1199-1201.
[20] Mansour W, Lemoine M, Neri Pinto F, et al. Markers of hepatitis delta virus infection can be detected in follicular fluid and semen. J Clin Virol, 2014, 61(2): 279-281.
[21] Ma B O, Shim S G, Yang H J. Association of erectile dysfunction with depression in patients with chronic viral hepatitis. World J Gastroenterol, 2015, 21(18): 5641-5646.
[22] Chung S D, Keller J J, Liang Y C, et al. Association between viral hepatitis and erectile dysfunction: a population-based case-control analysis. J Sex Med, 2012, 9(5): 1295-1302.
[23] Pircher J, Czermak T, Merkle M, et al. hepatitis c virus induced endothelial inflammatory response depends on the functional expression of tnfalpha receptor subtype 2. PLoS One, 2014, 9(11): e113351.
[24] Maimone S, Saffioti F, Oliva G, et al. Erectile dysfunction in compensated liver cirrhosis. Dig Liver Dis, 2019, 51(6): 843-849.
[25] Calzo J P, Austin S B, Charlton B M, et al. Erectile dysfunction in a sample of sexually active young adult men from a us cohort: demographic, metabolic, and mental health correlates. J Urol, 2020, 101097ju0000000000001367.
[26] Ning L, Yang L. Hypertension might be a risk factor for erectile dysfunction: a meta-analysis. Andrologia, 2017, 49(4): e12644.
[27] Dove L M, Rosen R C, Ramcharran D, et al. Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology, 2009, 137(3): 873-884, 84.e1.
[28] Durazzo M, Premoli A, Di Bisceglie C, et al. Alterations of seminal and hormonal parameters: an extrahepatic manifestation of hcv infection?World J Gastroenterol, 2006, 12(19): 3073-3076.
[29] El-Sakka A I. Dehydroepiandrosterone and erectile function: a review. World J Mens Health, 2018, 36(3): 183-191.
[30] Raff H, Sluss P M. Pre-analytical issues for testosterone and estradiol assays. Steroids, 2008, 73(13): 1297-1304.
[31] Sinclair M, Grossmann M, Gow P J, et al. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol, 2015, 30(2): 244-251.
[32] Sinclair M, Gow P J, Angus P W, et al. High circulating oestrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease. Liver Int, 2016, 36(11): 1619-1627.
[33] Paternostro R, Heinisch B B, Reiberger T, et al. Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. Hepatol Res, 2019, 49(2): 201-211.
[34] Zifroni A, Schiavi R C, Schaffner F. Sexual function and testosterone levels in men with nonalcoholic liver disease. Hepatology, 1991, 14(3): 479.
[35] 倪东升, 王天才. 一氧化氮在肝硬化大鼠睾丸功能障碍发生中的作用. 中华肝脏病杂志, 2002, 10(4): 294-296.
[36] Gluud C, Wantzin P, Eriksen J. No effect of oral testosterone treatment on sexual dysfunction in alcoholic cirrhotic men. Gastroenterology, 1988, 95(6): 1582-7.
[37] Porst H, Gacci M, Buttner H, et al. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. European urology, 2014, 65(2): 455-464.
[38] 黄燕平, 郑伏甫, 姚凤娟, 等. 小剂量每日服用他达那非改善勃起功能障碍患者内皮舒张功能及勃起硬度的研究. 中华男科学杂志, 2010, 16(11): 1052-5.

男性慢性肝病患者勃起功能障碍研究进展^*

Erectile dysfunction in male patients with chronic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[2]	石翠翠, 刘彦君, 章瑞南, 李光明, 范建高. 肝硬化患者血脂异常分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 859-862.
[3]	柳梅, 时永红, 郇娟, 陈茂丽. 失代偿期肝硬化患者并发医院内感染病原菌类别及其耐药特点分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 863-866.
[4]	刘玉玲, 甄增国, 王慧娟, 万秀敏, 郭振凯. 益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 867-870.
[5]	邢莉, 杜倩影, 姜艳丽, 韩冬. 分段注射对比剂CT增强扫描提高乙型肝炎肝硬化患者肝静脉显影效果研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 871-874.
[6]	黄力鸥, 吴春荣, 徐丹, 崔宇慧, 唐建国. 无肝素化连续性肾脏替代治疗肝硬化并发肝性脑病患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 875-878.
[7]	叶东, 张俊霞, 李洁, 刘颖, 张丹, 郭永泽. 内镜下食管静脉曲张套扎术治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者再出血风险观察^*[J]. 实用肝脏病杂志, 2021, 24(6): 879-882.
[8]	韩成美, 韩永峰, 王春华. 乙型肝炎肝硬化患者并发急性肾损伤危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 883-886.
[9]	王菁, 毕宁, 方亮, 田园. 自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 887-890.
[10]	薛魁, 徐银海, 张健. 慢性乙型肝炎和乙型肝炎肝硬化患者血清血小板生成素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(6): 891-894.
[11]	韩利畴, 许望, 韩丹, 邢增珀. 慢性乙型肝炎和乙型肝炎肝硬化患者胃粘膜病变研究[J]. 实用肝脏病杂志, 2021, 24(6): 895-898.
[12]	束青华, 张楠楠, 葛勇胜. 不同HCV基因型感染的慢性丙型肝炎和肝硬化患者对重组人干扰素α-2a治疗应答的影响[J]. 实用肝脏病杂志, 2021, 24(6): 899-902.
[13]	赵剑波, 谭卿. 非肝硬化性门静脉高压症研究进展[J]. 实用肝脏病杂志, 2021, 24(5): 613-616.
[14]	谭风雷, 吴亮亮, 邓泽润, 徐峥, 张洁, 张跃新. 夜间加餐对肝硬化患者影响的Meta分析[J]. 实用肝脏病杂志, 2021, 24(5): 625-628.
[15]	李伟, 宋卫东, 谢巴图白音. 采用EVL或TIPS治疗肝硬化并发食管静脉曲张出血患者疗效及其预后分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 629-632.